Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.55Last Year’s EPS
-0.45Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a mix of strong operational momentum (notably ~69% Q4 procedure growth, 42% installed-base growth, international expansion, a healthy cash balance and explicit 2026 revenue/procedure guidance) and near-term headwinds (Q4 gross margin shortfall, widened net loss and adjusted EBITDA loss, higher OpEx and temporary commercial disruption). Management implemented deliberate changes—eliminating bulk discounts, realigning commercial organization and creating a launch team—that caused short-term revenue impact but are intended to improve ASP, predictability of revenue and time-to-value. Given the substantial top-line and procedural growth, clear multi-year guidance and an articulated path toward narrowing losses and positive Q4 2026 EBITDA, the positives outweigh the near-term negatives while acknowledging execution risk during the transition.Company Guidance
Strong Procedure Growth
Completed ~12,200 U.S. procedures in Q4 2025, representing ~69% year-over-year growth — signaling strong clinical adoption momentum.
Revenue Growth in Quarter and Guidance for 2026
Q4 2025 total revenue of $76.4M, up 12% YoY. Management reset 2026 revenue guidance to $390M–$410M, implying ~27%–33% growth versus 2025.
Installed Base and System Placements Expansion
Sold 65 new HYDRO systems in Q4; installed base reached 718 systems, a 42% increase versus year-end 2024; Q4 system revenue of $27.6M at ~ $425K blended ASP.
Consumables Revenue Growth and Handpiece ASP Improvement
Total U.S. handpiece plus consumable revenue of $34M in Q4, up 16% YoY. Q4 handpiece ASP rose to ~$3,340, up ~$140 (~5% sequentially); management now targets ~$3,500 ASP for 2026 (~9% lift vs 2025).
International Revenue Momentum
International revenue of $9.8M in Q4, up 25% year-over-year, and management guiding international revenue of ~$50M–$51M for 2026.
Cash Position Provides Runway
Cash, cash equivalents and restricted cash totaled $285M as of December 31, 2025, supporting operations, investments and the path to profitability.
Path to Profitability and Improving EBITDA Outlook
Company expects full-year 2026 adjusted EBITDA loss of $30M to $17M with positive adjusted EBITDA in Q4 2026 at both low and high revenue scenarios — signaling narrowing losses and seasonal profitability cadence.
Procedure Volume Outlook for 2026
Guidance for total U.S. procedures in 2026 of 60,000–64,000, representing ~39%–48% growth versus 2025, indicating confidence in accelerating utilization.
Commercial Operating Changes and Early Launch Team Results
Realigned commercial organization into integrated regional structure and created a dedicated launch team; pilot showed ~50% reduction in time-to-first-line cases, aimed at faster, more consistent launches and improved downstream utilization.
Contained One-Time Field Action
Voluntary field action in Q4 was nonrecurring (~$1.5M impact), resolved via a field upgrade with no patient safety issues and not expected to recur.
PRCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $27.84 | $23.63 | -15.12% |
Nov 04, 2025 | $35.02 | $31.61 | -9.74% |
Aug 06, 2025 | $45.69 | $39.59 | -13.35% |
Apr 24, 2025 | $55.70 | $52.56 | -5.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PROCEPT BioRobotics (PRCT) report earnings?
PROCEPT BioRobotics (PRCT) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is PROCEPT BioRobotics (PRCT) earnings time?
PROCEPT BioRobotics (PRCT) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRCT EPS forecast?
PRCT EPS forecast for the fiscal quarter 2026 (Q1) is -0.55.